Jupiter Topco LLC Takes $973,000 Position in Immunome, Inc. $IMNM

Jupiter Topco LLC acquired a new position in Immunome, Inc. (NASDAQ:IMNM) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 45,900 shares of the company’s stock, valued at approximately $973,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Primecap Management Co. CA purchased a new stake in Immunome in the second quarter valued at approximately $97,081,000. Parkman Healthcare Partners LLC purchased a new position in shares of Immunome during the second quarter worth $12,591,000. Legal & General Group Plc purchased a new position in shares of Immunome during the second quarter worth $1,899,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Immunome in the second quarter valued at $3,664,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Immunome in the second quarter valued at $254,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

IMNM opened at $26.76 on Friday. Immunome, Inc. has a one year low of $8.66 and a one year high of $30.06. The company has a market cap of $3.04 billion, a P/E ratio of -10.58 and a beta of 2.13. The business’s 50-day simple moving average is $24.96 and its 200-day simple moving average is $22.57.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, analysts predict that Immunome, Inc. will post -2.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IMNM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Wedbush lifted their target price on Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Barclays started coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Finally, Citigroup restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Insider Transactions at Immunome

In related news, Director Isaac Barchas sold 11,048 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the sale, the director directly owned 92,211 shares of the company’s stock, valued at $2,512,749.75. The trade was a 10.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total value of $2,273,555.44. Following the sale, the insider owned 50,366 shares in the company, valued at $1,263,682.94. This trade represents a 64.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 682,310 shares of company stock worth $15,675,566. 7.21% of the stock is currently owned by insiders.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.